Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer

Anticancer Research

Volumn 24, Issue 6, 2004, Pages 4223-4226

  Frontini, Luciano ^a   Lissoni, P ^a   Vaghi, M ^a   Perego, M S ^a   Pescia, S ^a   Ardizzoia, A ^a   Gardani, G ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Breast cancer; Cabergoline; Hyperprolactinemia

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BROMOCRIPTINE; CABERGOLINE; DOCETAXEL; DOPAMINE RECEPTOR STIMULATING AGENT; GROWTH FACTOR; HORMONE RELEASE INHIBITING FACTOR; LONG ACTING DRUG; PROLACTIN; ERGOLINE DERIVATIVE; TAXOID;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METASTASIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RANDOMIZED CONTROLLED TRIAL; BLOOD; BREAST TUMOR; DRUG ADMINISTRATION; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ERGOLINES; FEMALE; HUMANS; MIDDLE AGED; PROLACTIN; TAXOIDS;

EID: 14944376702     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Welsch C and Nagasawa H: Prolactin and murine tumorigenesis: a new review. Cancer Res 37: 951-963, 1977.
2. Holtkamp w, Nagel CA, Wander HE, Rauschecker HF and Meyden C: Hyperprolactinemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int J Cancer 34: 323-328, 1984.
3. Wang DY, Hampson S and Kwa HG: Serum prolactin levels in women with breast cancer and their relationship to survival. Eur J Cancer Clin Oncol 22: 487-492, 1986.
4. Bhatavdekar JM, Shan NG, Balar DB et al: Plasma prolactin is an indicator of disease progression in advanced breast cancer. Cancer 65: 2028-2032, 1990.
5. Lissoni P, Vaghi M, Ardizzoia A et al: Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Neuroendocrinol Lett 22: 27-29, 2001.
6. Lissoni P, Bukovec R, Malugani F et al: A clinical study of taxotere versus taxotere plus the antiprolactinemic agent bromocriptine in metastatic breast cancer pretreated with anthracyclines. Anticancer Res 22: 1131-1134, 2002.
7. Lissoni P, Mandalà M, Giani L et al: Efficacy of bromocriptine in the treatment of metastatic breast cancer-and prostate cancer-related hyperprolactinemia. Neuroendocrinol Lett 21: 405-408, 2000.
8. Tumosito J and Mannisto P: Neurotransmitter regulation of anterior pituitary hormones. Pharmacol Rev 37: 249-332, 1985.
9. Lissoni P, Vaghi M, Villa S et al: Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline. Anticancer Res 23: 733-736, 2003.
10. Kondo Y, Imai Y, Hojo H, Endo T and Nozoe S: Suppression of tumor cell growth and mitogen response by apomorphine alkaloids, dicentrine, glaucine, corydine and apomorphine. J Pharmacobiodyn 13: 426-431, 1990.
11. Rubinow DR: Brain, behaviour and immunity: an interactive system. J Natl Cancer Inst Monogr 10: 79-82, 1990.
12. Lissoni P, Messina G, Vaghi M et al: A psychoneuroendocrine study of brain dopaminergic sensitivity in locally limited or metastatic cancer patients. In Vivo 16: 647-650, 2004.
13. Ben-Jonathan N: Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6: 564-589, 1985.
14. Lissoni P, Cangemi P, Pirato D et al: A review on cancer-psychospiritual status interaction. Neuroendocrinol Lett 22: 175-180, 2001.